Boston, MA 05/23/2014 (wallstreetpr) – Merrimack Pharmaceuticals Inc (NASDAQ:MACK) announced on May 22, 2014, that it intends to present its detailed analysis based on clinical data on explicitly innovative antibody cancer therapeutics at the American Society Of Clinical Oncology 2014 (ASCO 2014) Annual Meet, to be held at McCormick Place, Chicago. The four novel presentations shall showcase MACK’s expertise and clinical analysis in the realm of oncology.
The Co-Founder’s Insights
A Ph.D, Senior Vice President and Co-Founder at Merrimack, Gavin Mac Breath hailed the exciting opportunity at hand to share the details of Phase II data of MACK’s MM-121 Program. He further sounded ecstatic and snapped that often when patients do not show positive symptoms of healing by the application of currently available anticancer drugs, shall be relieved and benefited by a significant gamut when the commonly charged drugs are used in combination with MACK’s MM-121!
The Co-Founder also added that the successful research and clinical data pertaining to MM-121 has reaped and infused confidence in carrying forth the ongoing Phase II study of MM-111, which is expected to evolve as an elixir, anti-gastric-cancer drugs in the days to come. The company is also looking forward to share detailed Phase I data from Project MM-141 and Program MM-151. These therapeutic advancements are deemed to lead to sumptuous Phase 2 development; besides, MACK also seeks to venture into development of nanoliposome, MM-302.
The Basis Of Clinical Research
The system biology platform comprises an integrated approach of Biology, Computing and Engineering, to ensure a comprehensive understanding and analysis of tumor growth, survival strategies and measures to counteract the cancerous growth of tissues. Merrimack seeks to deploy proprietary antibodies and advanced nanoliposomal technologies to target cancers precisely, based on subtle signaling pathways and targeting tumor microenvironments.
Robert Mulroy, CEO and President of Merrimack Pharmaceuticals Inc (NASDAQ:MACK) feel that rigorous and detailed understanding of Cancer Biology is bound to transform cancer care in due course of time. Further, MACK’s expertise and diagnostic capabilities will offer myriad opportunities that lead to successful treatments for patients in the days to come.
Stock Boosts Up, After Announcement
The stocks of Merrimack Pharmaceuticals Inc (NASDAQ:MACK) have jumped up after the company announced about its plans, propositions and ideas to participate in ASCO Meet. Priced at $7.35/share, the stock might rise past its 1 year high mark of 7.37, provided its presentations are accepted with immense fervor in the 2014 ASCO Meet.
